Bile Acid Transporters – Function and Clinical Relevance

What Are Bile Acid Transporters?

Bile acid transporters are membrane-bound transport proteins that facilitate the directed movement of bile acids (also called bile salts) across cell membranes. They are primarily found in the liver, small intestine, and kidneys, and play a central role in the enterohepatic circulation – the physiological cycle by which bile acids, after being secreted into the intestine, are reabsorbed and returned to the liver.

Bile acids are biologically active molecules synthesized in the liver from cholesterol. They are stored in the gallbladder and released into the small intestine, where they are essential for emulsifying dietary fats and enabling the absorption of fat-soluble vitamins (A, D, E, and K).

Key Bile Acid Transporters

Several classes of bile acid transporters fulfill distinct roles in different organs:

Hepatic Transporters

• NTCP (Sodium-Taurocholate Cotransporting Polypeptide, SLC10A1): Mediates the uptake of conjugated bile acids from the portal blood into hepatocytes. It is sodium-dependent and is the primary uptake transporter in the liver.
• OATP1B1 and OATP1B3 (Organic Anion Transporting Polypeptides): Sodium-independent transporters that take up bile acids and other organic anions into hepatocytes.
• BSEP (Bile Salt Export Pump, ABCB11): Actively pumps bile acids from hepatocytes into the bile canaliculi. Mutations in the BSEP gene are associated with severe liver diseases.
• MRP2 (Multidrug Resistance-associated Protein 2, ABCC2): Transports conjugated bile acids and other organic anions into bile.

Intestinal Transporters

• ASBT (Apical Sodium-dependent Bile Acid Transporter, SLC10A2): Responsible for the active reabsorption of conjugated bile acids in the terminal ileum. It is the key transporter maintaining the enterohepatic circulation.
• OSTalpha/OSTbeta (Organic Solute Transporter): Located on the basolateral side of enterocytes, these transporters move bile acids from intestinal cells into the portal bloodstream for return to the liver.

Renal Transporters

• ASBT (SLC10A2): Also expressed in the kidney, where it prevents urinary loss of bile acids through tubular reabsorption.

The Enterohepatic Circulation

The enterohepatic circulation describes the pathway by which bile acids travel from the intestine back to the liver. Approximately 95% of secreted bile acids are reabsorbed in the terminal ileum each day and transported via the portal vein back to the liver, where they are taken up again by hepatocytes and re-secreted into bile. Only a small fraction of bile acids is lost daily and must be replenished by de novo synthesis from cholesterol.

Bile acid transporters are the molecular key components that sustain this cycle. Dysfunction of any one of these transporters can lead to bile acid accumulation in affected cells or tissues, causing significant damage.

Clinical Significance – Diseases Caused by Transporter Defects

Genetic mutations or acquired dysfunction of bile acid transporters can result in a range of conditions:

• Progressive Familial Intrahepatic Cholestasis (PFIC): A rare inherited disorder in which defects in transport proteins such as BSEP (PFIC type 2) or MDR3 (PFIC type 3) cause bile acid accumulation in the liver, leading to severe liver damage.
• Intrahepatic Cholestasis of Pregnancy (ICP): A pregnancy-related liver condition associated with impaired bile acid secretion.
• Bile Acid Malabsorption (BAM): Dysfunction of the ASBT transporter in the ileum leads to insufficient reabsorption of bile acids. Excess bile acids entering the colon cause secretory diarrhea.
• Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC): Inflammatory diseases of the bile ducts in which transporter function may be secondarily impaired.
• Drug-Induced Liver Injury (DILI): Many medications inhibit bile acid transporters, particularly BSEP, which can result in drug-induced cholestasis.

Therapeutic Relevance

Understanding bile acid transporters has direct therapeutic applications:

• ASBT Inhibitors: Inhibitors of the ASBT transporter (e.g., odevixibat, maralixibat) are used to treat PFIC and other cholestatic liver diseases. By blocking bile acid reabsorption in the gut, they interrupt the enterohepatic circulation and reduce the bile acid burden on the liver.
• Bile Acid Sequestrants: Cholestyramine and other ion-exchange resins bind bile acids in the intestine, preventing their reabsorption. They are used to treat elevated cholesterol levels and bile acid-induced diarrhea.
• NTCP as an Entry Receptor for Hepatitis B and D: The hepatic uptake transporter NTCP has been identified as a cellular receptor for both hepatitis B virus (HBV) and hepatitis D virus (HDV). This discovery opened new antiviral treatment strategies, including the drug bulevirtide, which blocks NTCP to prevent viral entry into liver cells.

References

1. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology. 2004;126(1):322-342.
2. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiological Reviews. 2003;83(2):633-671.
3. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on genetic metabolic liver diseases. Journal of Hepatology. 2022;77(4):1031-1079.